CCCC Jan 2025 5.000 call
| Previous close | 1.0000 |
| Open | 1.0000 |
| Bid | 0.0000 |
| Ask | 1.4000 |
| Strike | 5.00 |
| Expiry date | 2025-01-17 |
| Day's range | 1.0000 - 1.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 429 |
Insider MonkeyC4 Therapeutics, Inc. (CCCC): Is This the Best Biotech Penny Stock to Buy Now?
We recently compiled a list of the 10 Best Biotech Penny Stocks to Buy Now. In this article, we are going to take a look at where C4 Therapeutics, Inc. (NASDAQ:CCCC) stands against the other biotech penny stocks. Biotech Stocks in 2024: Growth Prospects, Key Players, and Investment Opportunities In 2024, the healthcare industry has […]
Simply Wall St.It Looks Like C4 Therapeutics, Inc.'s (NASDAQ:CCCC) CEO May Expect Their Salary To Be Put Under The Microscope
Key Insights C4 Therapeutics will host its Annual General Meeting on 20th of June Salary of US$639.0k is part of CEO...
GlobeNewswireC4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform the Board to Lead C4T into Next Phase of Growth WATERTOWN, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted p
